KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Cash from Financing Activities readings, the most recent being -$218.0 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 5320.54% to -$218.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$349.9 million, a 5974.14% decrease, with the full-year FY2025 number at -$349.9 million, down 5974.14% from a year prior.
  • Cash from Financing Activities hit -$218.0 million in Q4 2025 for Biocryst Pharmaceuticals, down from -$58.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $347.4 million in Q4 2021 to a low of -$218.0 million in Q4 2025.
  • Median Cash from Financing Activities over the past 5 years was $1.2 million (2023), compared with a mean of $6.2 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 19870.07% in 2023 and later plummeted 5320.54% in 2025.
  • Biocryst Pharmaceuticals' Cash from Financing Activities stood at $347.4 million in 2021, then plummeted by 98.79% to $4.2 million in 2022, then plummeted by 175.57% to -$3.2 million in 2023, then decreased by 26.73% to -$4.0 million in 2024, then plummeted by 5320.54% to -$218.0 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$218.0 million (Q4 2025), -$58.8 million (Q3 2025), and -$73.7 million (Q2 2025) per Business Quant data.